GlassScriptPhysician profile
Corie Johnson Grabowski
NPI 1023527264
$4,346.93
in general payments reported to CMS, 2019-2025
27 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.89 · 2024: $3,129 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Travel and Lodging: $1,413 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.96 |
| Travel and Lodging | $1,412.97 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,787.96 | 2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $366.44 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $302.81 | 2024-2025 | Ams 700, General - Erectile Dysfunction, Axonics |
| Endo USA, INC. | $282.90 | 2024-2025 | Xiaflex, Aveed |
| Srs Medical Systems, INC. | $248.34 | 2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Astellas Pharma US INC | $179.17 | 2024-2025 | Xtandi |
| Tolmar, INC. | $162.98 | 2024-2025 | Jatenzo, Eligard, Rubraca |
| Medtronic, INC. | $154.57 | 2024-2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $149.98 | 2023-2025 | |
| Tempus Ai, INC | $140.63 | 2024-2025 | Xt Cdx |
| Dendreon Pharmaceuticals LLC | $139.18 | 2024-2025 | Provenge |
| Teleflex LLC | $89.78 | 2024-2025 | Urolift, Barrigel |
| Ferring Pharmaceuticals INC. | $39.28 | 2025 | Adstiladrin |
| Urogen Pharma, INC. | $36.56 | 2025 | |
| Pharmaand Gmbh | $29.60 | 2025 | Rubraca |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.66 | 2024 | |
| Janssen Biotech, INC. | $27.21 | 2025 | Carvykti, Rybrevant |
| Abc Home Medical Supply, INC. | $24.78 | 2024 | |
| Ethicon US, LLC | $20.95 | 2025 | Vistaseal |
| Calyxo, INC. | $20.58 | 2025 | Cvac Aspiration System |
| Astrazeneca Pharmaceuticals LP | $19.97 | 2024 | Lynparza |
| Antares Pharma, INC. | $19.32 | 2025 | Xyosted |
| Immunitybio, INC. | $17.41 | 2025 | |
| Pfizer INC. | $17.07 | 2024 | |
| Verity Pharmaceuticals INC. | $15.54 | 2024 | Trelstar |
| Olympus America INC. | $14.18 | 2025 | Itind System |
| Laborie Medical Technologies Corp. | $11.08 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corie Grabowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.